Arrowhead Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 525
- Market Cap
- $2.9B
- Introduction
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
Plozasiran Shows Promise in Reducing Cholesterol and Triglycerides in Mixed Hyperlipidemia Patients
Plozasiran, an investigational hepatocyte-targeted APOC3 small interfering RNA developed by Arrowhead Pharmaceuticals, demonstrated significant reductions in triglyceride levels and improved lipid profiles in patients with mixed hyperlipidemia.
RAGE Inhibitor Pipeline Shows Promise for Inflammatory Diseases with 5+ Companies Advancing Novel Therapeutics
A comprehensive pipeline analysis reveals over five companies developing RAGE inhibitors across multiple clinical stages, with promising applications in chronic inflammatory diseases and neurodegenerative disorders.
Arrowhead's Plozasiran for Familial Chylomicronemia Syndrome Fast-Tracked for EU Approval
Arrowhead Pharmaceuticals' plozasiran, a novel treatment for familial chylomicronemia syndrome (FCS), has been filed for review by the European Medicines Agency and is being fast-tracked for potential EU marketing approval.
Epicrispr Biotechnologies Secures $68 Million to Advance First Epigenetic Therapy for FSHD
Epicrispr Biotechnologies has raised $68 million in Series B funding to develop EPI-321, a first-in-class epigenetic therapy targeting facioscapulohumeral muscular dystrophy (FSHD).
Arrowhead's ARO-C3 Shows Promising Results in IgA Nephropathy Trial with 89% Reduction in C3 Levels
Arrowhead Pharmaceuticals' ARO-C3 demonstrated significant efficacy in IgA nephropathy patients, achieving mean C3 reductions of 89% and sustained reductions exceeding 87% through week 24 of the Phase 1/2 trial.
JPM25: Pfizer Focuses on Obesity, Regeneron Anticipates Key Data, BioNTech Expands Cancer Pipeline
Pfizer is prioritizing its oral obesity drug, danuglipron, with late-stage studies planned for the second half of 2025, aiming for a novel mechanism of action.
Landmark Cardiology Advancements: Novel Therapies and Key Trial Results in 2024
Tirzepatide shows promise in reducing heart failure hospitalization or cardiovascular death by 38% in obese patients with HFpEF.
Ionis' Tryngolza Approved for FCS as Arrowhead's Plozasiran Awaits FDA Review
The FDA has approved Ionis Pharmaceuticals' Tryngolza (olezarsen) as the first treatment for adults with familial chylomicronemia syndrome (FCS).
RNA Therapy Market Set to Reach $4.16 Billion by 2034 as Clinical Trials Accelerate
The global RNA therapy clinical trials market is projected to grow from $2.85 billion in 2024 to $4.16 billion by 2034, with a CAGR of 3.85%, driven by advancements in mRNA, siRNA, and antisense oligonucleotide-based therapies.
Arrowhead Initiates Phase I/IIa Trial of RNAi Therapy ARO-INHBE for Obesity
Arrowhead Pharmaceuticals has dosed the first patient in a Phase I/IIa trial of ARO-INHBE, an RNAi therapeutic targeting obesity.